Therapeutic Research

Abstract

Among neuroendocrine neoplasms（NEN）, neuroendocrine tumors（NET）with a high degree of differentiation and a relatively low growth potential involve various primary organs and often require treatment for a long duration. Accordingly, in their diagnosis and treatment, cooperation with multiple professions cross‒departmentally within the hospital and medical network with regional medical institutions are important. Medical and multidisciplinary treatment is specifically recommended for patients with pancreatic/gastrointestinal NET with locally advanced and unresectable lesions or metastatic lesions. Peptide receptor radionuclide therapy（PRRT）has recently been approved in Japan and treatment options are increasing in this regard. This article reviews the latest trend of therapeutic agents for NET focusing on PRRT, and introduces efforts for the collaboration between hospitals in the advancement of PRRT.